Pair Name | Lycopene, Enzalutamide | ||
Phytochemical Name | Lycopene (PubChem CID: 446925 ) | ||
Anticancer drug Name | Enzalutamide (PubChem CID: 15951529 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Lycopene, Enzalutamide | |||
Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Down-regulation | Expression | AR | hsa367 | |
Down-regulation | Phosphorylation | EZH2 | hsa2146 | |
Down-regulation | Expression | MMP2 | hsa4313 | |
Down-regulation | Expression | MMP9 | hsa4318 | |
Down-regulation | Expression | PCNA | hsa5111 | |
In Vitro Model | LNCaP C4-2B | Prostate carcinoma | Homo sapiens (Human) | CVCL_4784 |
22Rv1 | Prostate carcinoma | Homo sapiens (Human) | CVCL_1045 | |
In Vivo Model | 22RV1 cells (2×10⁶) were injected into left tibia or the right flank of nude mice. | |||
Result | These results suggest that the enhanced antitumor effects of enzalutamide by lycopene may be related to the reduction of AR protein levels through lycopene-mediated inhibition of AKT/EZH2 pathway, which may provide a new approach to improve the efficacy of enzalutamide in CRPC. |
No. | Title | Href |
---|---|---|
1 | Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. Biochem Biophys Res Commun. 2022 Jul 12;613:53-60. doi: 10.1016/j.bbrc.2022.04.126. | Click |